Sponsored by
This is a new form of targeted radiation. We did a webinar about it: https://virtualtrials.org/video2022.cfm?video=202205. They reported on the early results of their phase 1 trial, which was a dose escalation trial. They reported an amazing median survival of 10 months. They did not have an external control group but in general, people with leptomeningeal mets only live 2 weeks to 4 months. As the find the correct dosages it should get better. And as I always say - combinations are the way to cure these things. In the past, the main problem was that nothing really had time to work. Now, if you could buy 10 months - that gives you a lot of time for other treatments to work. Very exciting.
Disclaimer: Plus Therapeutics is a sponsor of our organization.